HLS-Rugged point-of-care device for global hemostasis testing of whole blood

描述（由申请人提供）：Rheomics正在开发一种使用全血的全球止血试验。它将使与创伤相关的凝血病的更快诊断和目标导向治疗成为可能。它将降低与血液制品治疗相关的发病率、死亡率和费用。我们的设备测量凝血时间，动力学，刚度和裂解。与现有的

DESCRIPTION (provided by applicant): Rheomics is developing a global hemostasis test that uses whole blood. It will enable faster diagnosis and goal-directed therapy of coagulopathies associated with trauma. It will reduce morbidity, mortality, and costs associated with blood product therapy. Our device measures clotting time, kinetics, stiffness, and lysis. Unlike existing devices, ours will use an inexpensive, disposable microfluidic test strip and a robust, easy-to-use analyzer. Our goal is to improve care for the many patients-as many as 6.2 million, just in the US-who develop a coagulation dysfunction that triples their chance of dying. At the same time, we can save hundreds of dollars per patient and hundreds of thousands of dollars for hospital systems.